针对KRASG12V的自然TCR显示出精细的特异性和对人类固体瘤的敏感性
Adham S Bear1, Rebecca B Nadler2, Mark H O'Hara1,3
1Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine.
The Journal of clinical investigation
|September 17, 2024
概括
这项研究确定了特定于KRASG12V新抗原的T细胞受体 (TCR),在临床前模型中显示出强大的抗瘤活性. 这些KRASG12V特异性TCR显示出开发针对KRAS突变癌症的新型TCR-T细胞疗法的巨大潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- KRAS-突变 (KRASMUT) 新抗原已被识别,但T细胞受体 (TCR) 的特异性尚不清楚.
- 了解TCR对KRAS新抗原的反应对于癌症免疫治疗至关重要.
研究的目的:
- 调查KRASMUT免疫性,并对向KRASG12V.V.的TCR进行表征.
- 评估HLA-A3超级家族等位基因中的KRASG12V特异性TCRs的治疗潜力.
主要方法:
- 第1期临床疫苗试验针对KRASMUT.
- 隔离和全面分析KRASG12V特异性的TCRs (特异性,亲和性,交叉反应性,CD8依赖性).
- 通过定量免疫组学评估TCR溶解活性和抗原密度.
主要成果:
- 接种疫苗诱导了CD8+和CD4+T细胞对KRASMUT的反应.
- 特定于KRASG12V的TCR显示出对突变蛋白的高特异性,没有KRASWT反应性.
- 限制HLA-A*03:01和限制HLA-A*11:01的TCR都显示出强大的抗癌激活活性,其中一些CD4+TCR显示出效应器功能.
结论:
- 特定于KRASG12V的TCR在TCR-T细胞治疗的开发中具有很高的治疗潜力.
- 已识别的TCR对低抗原水平敏感,这表明在各种瘤环境中具有有效性.
更多相关视频
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:38The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K